All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2016-11-16T13:34:16.000Z

Over 40 years of Rai CLL staging system celebrated

Nov 16, 2016
Share:

Bookmark this article

Blood are currently celebrating their 70th year by featuring flashbacks of key papers from their history, accompanied by new editorials. One of these flashbacks featured the seminal paper by Rai et al. in which they described a system to stage and predict CLL patient outcome through a physical exam and complete blood count.

The Rai system has five stages and the original publication incorporated data from 125 CLL patients. The authors in this publication helped to illustrate the value of grouping a large number of patients together in order to better understand CLL patient prognosis and ultimately help improve patient outcome. Due to the system being simple and based on just two criteria, it is commendable that over 40 years after publication the Rai staging system is still being used. The Lymphoma Hub congratulates both Rai et al. on their landmark publication and Blood on celebrating their 70th anniversary.

Original Rai et al. Abstract:

Clinical staging of chronic lymphocytic leukemia

A method of clinical staging of chronic lymphocytic leukemia (CLL) has been proposed which is based on the concept that CLL is a disease of progressive accumulation of nonfunctioning lymphocytes: stage O, bone marrow and blood lymphocytosis only; stage 1, lymphocytosis with enlarged nodes; stage II, lymphocytosis with enlarged spleen or liver or both; stage III, lymphocytosis with anemia; and stage IV:lymphocytosis with thrombocytopenia. Analysis of 125 patients. in the present series showed the following median survival times (in months) from diagnosis: stage 0, is greater than 150; stage I 101; stage II, 71; stage III, 19; stage IV, 19, The median survival for the entire series was 71 mo. The prognostic significance of the stage remained even after adjustment was made for age and sex. However, both sex and age were shown to be poor predictors of survival after adjustment for stage. The method of staging proved to be a reliable predictor of survival whether used at diagnosis or during the course of the disease. The proposed staging system was an equally accurate indicator for survival when applied to two other previously published studies of large series of patients.

  1. Rai K.R. et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46(2):219–234.
  2. Blood Editors. Blood Flashback Editorial. Blood. 2016; 128:2109; doi:10.1182/blood-2016-08-737650.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox